17. Phase II reversal of enzalutamide resistance cohort ONLY Patients with histologically confirmed adenocarcinoma of the prostate that have progressed after at least 1 line of taxane based therapy and progressed on enzalutamide treatment (having received a minimum of 12 weeks enzalutamide) within 6 months prior to entry (day of starting IMP). Prior treatment with abiraterone is not an exclusion criteria.